<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912063</url>
  </required_header>
  <id_info>
    <org_study_id>M20-866</org_study_id>
    <secondary_id>2021-000514-41</secondary_id>
    <nct_id>NCT04912063</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination With Venetoclax and/or Azacitidine in Subjects With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low&#xD;
      survival rate and few options for participants who are unable to undergo intensive&#xD;
      chemotherapy, the current standard of care. This study is to evaluate how safe lemzoparlimab&#xD;
      is and how it moves within the body when used along with azacitidine and/or venetoclax in&#xD;
      adult participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).&#xD;
      Adverse events and maximum tolerated dose (MTD) of lemzoparlimab will be assessed.&#xD;
&#xD;
      Lemzoparlimab (TJ011133) is being evaluated in combination with azacitidine and venetoclax&#xD;
      for the treatment of acute myeloid leukemia (AML) and with azacitidine with/without&#xD;
      venetoclax for myelodysplastic syndrome (MDS). Study doctors place the participants in 1 of 5&#xD;
      groups, called treatment arms. Each group receives a different treatment. Adult participants&#xD;
      with a diagnosis of AML or MDS will be enrolled. Around 80 participants will be enrolled in&#xD;
      the study in approximately 50 sites worldwide.&#xD;
&#xD;
      Participants will receive lemzoparlimab (IV) once weekly (Q1W), venetoclax oral tablets once&#xD;
      daily (QD) for 28 days (AML participants) or 14 days (MDS participants) and Azacitidine by SC&#xD;
      or IV route QD for 7 days of each 28-day cycle.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests and&#xD;
      checking for side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">March 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 9, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) When Co-administered With Venetoclax and Azacitidine in Participants With Treatment-Naïve Acute Myeloid Leukemia (AML) Ineligible for Standard Induction Therapy</measure>
    <time_frame>Up to 30 days after first dose of study drug</time_frame>
    <description>DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) When Co-administered With Azacitidine With or Without Venetoclax in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndrome (MDS)</measure>
    <time_frame>Up to 30 days after first dose of study drug</time_frame>
    <description>DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response of Complete Remission (CR) for AML</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best overall response of complete remission (CR), defined as achieving CR according to modified international working group (IWG) 2003 criteria for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response of Composite CR (CRc) for AML</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best overall response of composite CR (CRc), [CR or CR with incomplete blood count recovery (CRi)] according to modified IWG 2003 criteria for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response of Complete Remission With Partial Hematologic Recovery (CRh) for AML</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best overall response of CRh, defined according to modified IWG 2003 criteria for AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) for AML</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Duration of response (DOR), defined for participants who achieve a best overall response, as the time from the first occurrence of response to disease progression/relapse from CR, CRi or CRh or death from disease progression, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) for AML</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Event-free survival (EFS), defined as time from first dose of any study drug (lemzoparlimab or venetoclax or azacitidine) to the date of progressive disease (PD), relapse from CR or CRi, treatment failure defined as failure to achieve CR, CRi or MLFS after at least 6 cycles of study treatment, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS ) for AML</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Overall survival (OS), defined as the time from the date of the first dose of any study drug (lemzoparlimab or venetoclax or azacitidine) to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response of CR, for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best overall response of CR per the modified IWG 2006 criteria for MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response of Marrow-Complete Remission (mCR), for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best overall response of marrow-complete remission (mCR), per the modified IWG 2006 criteria for MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response of CR or PR for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best overall response of CR or PR, per the modified IWG 2006 criteria for MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response of CR or PR or mCR, for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Best overall response of CR or PR or mCR, per the modified IWG 2006 criteria for MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement (HI), for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Hematologic improvement (HI), defined as a participant achieving erythroid/platelet/neutrophil responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell Transfusion Independence (TI), for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Red blood cell transfusion independence (TI), defined as a participant who is transfusion dependent at baseline achieved TI post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet TI, for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Platelet TI, defined as a participant who is transfusion dependent at baseline achieved TI post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR, for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>DOR, defined for participants who achieve a best overall response, as the time from the first occurrence of response (CR or mCR or PR) to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS), for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Progression Free Survival (PFS) defined as the time from the date of the first dose of any study drug to PD or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS, for MDS</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>OS, defined as the time from the date of the first dose of any study drug to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lemzoparlimab + Azacitidine in MDS (Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lemzoparlimab</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine in MDS (Escalation)</arm_group_label>
    <other_name>TJ011133</other_name>
    <other_name>ABBV-IMAB-TJC4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Subcutaneous Injection or Intravenous (IV) Injection/Infusion</description>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine in MDS (Escalation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)</arm_group_label>
    <arm_group_label>Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)</arm_group_label>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented confirmation of acute myeloid leukemia (AML) according to the World Health&#xD;
             Organization (WHO) criteria, previously untreated [OR]&#xD;
&#xD;
          -  Documented diagnosis of previously untreated de novo myelodysplastic syndrome (MDS)&#xD;
             according to the 2017 WHO classification with presence of &lt; 20% bone marrow blasts per&#xD;
             marrow biopsy/aspirate.&#xD;
&#xD;
          -  Participants with documented MDS must meet the following disease activity criteria:&#xD;
&#xD;
               -  Overall revised international prognostic scoring system (IPSS-R) score &gt; 3&#xD;
                  (intermediate, high, or very high);&#xD;
&#xD;
               -  Eastern cooperative oncology group (ECOG) performance status of 0 to 2;&#xD;
&#xD;
               -  Hematopoietic stem cell transplant (HSCT) ineligible, or participant who chooses&#xD;
                  not to undergo HSCT.&#xD;
&#xD;
          -  Participants with documented AML with adverse cytogenetic and/or molecular risk, and&#xD;
             must be considered ineligible for induction therapy defined by the following:&#xD;
&#xD;
               -  &gt;= 75 years of age; [OR]&#xD;
&#xD;
               -  &gt;= 18 to 74 years of age with at least one of the following comorbidities:&#xD;
&#xD;
                    -  Eastern cooperative oncology group (ECOG) performance status of 2 to 3;&#xD;
&#xD;
                    -  Cardiac history of congestive heart failure requiring treatment or ejection&#xD;
                       fraction &lt;= 50% or chronic stable angina;&#xD;
&#xD;
                    -  Diffusion capacity of lung (DLCO) &lt;= 65% or forced expiratory volume during&#xD;
                       the first second (FEV1) &lt;= 65%;&#xD;
&#xD;
                    -  Creatinine clearance &gt;= 30 mL/min to &lt; 45 mL/min;&#xD;
&#xD;
                    -  Moderate hepatic impairment with total bilirubin &gt; 1.5 to &lt;= 3.0 × upper&#xD;
                       limit of normal (ULN);&#xD;
&#xD;
                    -  Any other comorbidity that the physician judges to be incompatible with&#xD;
                       intensive chemotherapy or the participant declines to receive intensive&#xD;
                       chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with documented AML with acute promyelocytic leukemia and considered&#xD;
             eligible for induction therapy.&#xD;
&#xD;
          -  Participant with documented AML having prior diagnosis of:&#xD;
&#xD;
               -  Chronic myeloid leukemia with or without BCR-ABL1 translocation and AML with&#xD;
                  BCR-ABL1 translocation;&#xD;
&#xD;
               -  known active central nervous system involvement with AML.&#xD;
&#xD;
          -  Participants with documented MDS having prior diagnosis of:&#xD;
&#xD;
               -  Therapy-related MDS;&#xD;
&#xD;
               -  MDS evolving from a pre-existing myeloproliferative neoplasm (MPN);&#xD;
&#xD;
               -  MDS/MPN including chronic myelomonocytic leukemia, atypical chronic myeloid&#xD;
                  leukemia, juvenile myelomonocytic leukemia and unclassifiable MDS/MPN.&#xD;
&#xD;
          -  History of allogeneic HSCT or solid organ transplantation.&#xD;
&#xD;
          -  Previous exposure to azacitidine or venetoclax or anti-CD47 therapies.&#xD;
&#xD;
          -  History of an active malignancy within the past 2 years prior to Screening, with the&#xD;
             exception of:&#xD;
&#xD;
               -  Adequately treated carcinoma in situ of the cervix uteri or carcinoma in situ of&#xD;
                  the breast;&#xD;
&#xD;
               -  Adequately treated basal cell carcinoma or localized squamous cell carcinoma of&#xD;
                  the skin;&#xD;
&#xD;
               -  Asymptomatic prostate cancer without known metastatic disease and with no&#xD;
                  requirement for therapy;&#xD;
&#xD;
               -  Previous malignancy confined and surgically resected (or treated with other&#xD;
                  modalities) with curative intent.&#xD;
&#xD;
          -  Conditions that could interfere with drug absorption including but not limited to&#xD;
             short bowel syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - Main /ID# 227071</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles /ID# 227752</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center /ID# 228689</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - St Matthews /ID# 228378</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital /ID# 227273</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center /ID# 231083</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5400</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan /ID# 227030</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The John Theurer Cancer /ID# 228760</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Main Campus /ID# 228216</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University /ID# 227121</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania /ID# 227024</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Ctr /ID# 228048</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Texas Medical Center /ID# 227019</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health /ID# 227363</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital /ID# 227723</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Health /ID# 227717</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre /ID# 227863</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre /ID# 227867</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Duesseldorf /ID# 227751</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig /ID# 227750</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 227749</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 227748</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center /ID# 227389</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tel-Aviv</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center /ID# 227387</name>
      <address>
        <city>Tel Aviv-Yafo</city>
        <state>Tel-Aviv</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center-Hebrew University /ID# 227275</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 227738</name>
      <address>
        <city>Petakh Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas /ID# 226948</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Bologna Policlinico S.Orsola-Malpighi /ID# 226950</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda /ID# 226952</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 232498</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital /ID# 232466</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital /ID# 232451</name>
      <address>
        <city>Yamagata-shi</city>
        <state>Yamagata</state>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 227772</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz /ID# 227771</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria /ID# 227770</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trusts /ID# 229572</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Hospital /ID# 229578</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>Myelodysplastic Syndrome (MDS)</keyword>
  <keyword>Lemzoparlimab</keyword>
  <keyword>TJ011133</keyword>
  <keyword>ABBV-IMAB-TJC4</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>ABT-199</keyword>
  <keyword>GDC-0199</keyword>
  <keyword>VENCLEXTA</keyword>
  <keyword>VENCLYXTO</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

